SignalCorporate
GLP-1 may slow biological aging
GLP-1 may slow biological aging, a novel health claim.
Context
What happened: A randomized, placebo-controlled study published in Nature Communications reports that semaglutide slowed the accumulation of biological aging markers in the DNA of adults with HIV-associated lipohypertrophy.
Key numbers: 108 adults; about half received weekly semaglutide injections, the rest placebo; 32-week
Why it matters: The authors describe the result as a signal that semaglutide may slow some biological processes associated with aging, not a reversal of aging. They say larger trials are needed to confirm the findings and establish dosing and treatment duration.
What changed
A randomized, placebo-controlled study published in Nature Communications reports that semaglutide slowed the accumulation of biological aging markers in the DNA of adults with HIV-associated lipohypertrophy.
Why it matters
The authors describe the result as a signal that semaglutide may slow some biological processes associated with aging, not a reversal of aging. They say larger trials are needed to confirm the findings and establish dosing and treatment duration.